Patients with cachexia were older; had lower BMIs, weight at baseline and 1 year prior, and rates of comorbidities, such as dyslipidaemia, diabetes and atrial fibrillation; and were less likely to be treated with angiotensin‐converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) or anticoagulants. This evidence concerns the gene ACE and diabetes mellitus.